Navigation Links
BioSpecifics Technologies Corp. Announces Presentations at Two Upcoming Investor Conferences in March
Date:2/29/2012

LYNBROOK, N.Y., Feb. 29, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia, today announced that BioSpecifics' President, Tom Wegman, will present at the following upcoming investor conferences during the month of March 2012.

  • Cowen and Company 32nd Annual Health Care Conference (Boston, MA)
    Wednesday, March 7, 2012 at 10:40 a.m. EST
  • ROTH Capital Partners 24th Annual Conference (Laguna Niguel, CA)
    Tuesday, March 13, 2012 at 3:30 p.m. PDT (6:30 p.m. EDT)

The live webcasts of these presentations can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at www.biospecifics.com.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications. Its partner Auxilium Pharmaceuticals, Inc. markets XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture in adults with a palpable cord in the palm and is also developing XIAFLEX for the treatment of Peyronie's disease, which is currently in Phase 3 pivotal clinical trials, as well as for Frozen Shoulder (Adhesive Capsulitis) and cellulite which are in Phase 2 and Phase 1 respectively. Pfizer, Inc. is responsible for marketing XIAPEX® for Dupuytren's contracture in the 27 European Union member countries and 19 other European and Eurasian countries and also has commercialization and development rights for Peyronie's disease in these same territories. Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX for Dupuytren's contracture and Peyronie's disease in Japan and Actelion Pharmaceuticals has the development, supply and commercialization rights in Canada, Australia, Brazil and Mexico. BioSpecifics is developing XIAFLEX internally for human and canine lipomas. More information about the Company may be found on its website at www.biospecifics.com.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors
2. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2011 Financial Results on November 8, 2011
3. BioSpecifics Technologies Corp. Announces Data Presentations at Upcoming XVI Annual Federation of the European Societies for Surgery of the Hand Meeting
4. BioSpecifics Technologies Corp. Reports First Quarter 2011 Financial Results
5. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results
6. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2010 Financial Results on March 11, 2011
7. BioSpecifics Technologies Corp. to Present at Cowen and Company 31st Annual Health Care Conference
8. BioSpecifics Announces Positive Results From Clinical Trial in Canine Lipomas
9. BioSpecifics Technologies Corp. to Present at UBS Global Life Sciences Conference
10. BioSpecifics Technologies Corp. to Present at Rodman & Renshaw 12th Annual Healthcare Conference
11. Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... 2017 Interpace Diagnostics Group, Inc. (NASDAQ: ... clinically useful molecular diagnostic tests and pathology services, ... securities purchase agreement with three  institutional investors to ... stock in a registered direct offering.  In a ... sell to the same investors warrants to purchase ...
(Date:1/20/2017)... 20, 2017 Stock-Callers.com explores the ... influenced the most recent performances of select equities. In ... RGLS ), Abeona Therapeutics Inc. (NASDAQ: ... ), and Sage Therapeutics Inc. (NASDAQ: SAGE ... View Research, global Biotech market size is expected to reach $604.40 billion by ...
(Date:1/19/2017)... -- Market Research Future has a half cooked research report on Global ... rapidly and expected to reach USD 450 Million by the end ... ... been assessed as a swiftly growing market and expected that the ... future. There has been a tremendous growth in the prevalence of ...
(Date:1/19/2017)... ... January 19, 2017 , ... November ... to leading biopharmaceutical and medical device manufacturers and regulators, is proud to announce ... Part 11-compliant email client designed to provide product vigilance departments with the flexibility ...
Breaking Biology Technology:
(Date:12/15/2016)... 15, 2016 ... Research and Markets has announced the addition of the ... The report forecasts the global military biometrics market to grow ... The report has been prepared based on an in-depth market analysis with ... growth prospects over the coming years. The report also includes a discussion ...
(Date:12/15/2016)... Dec. 15, 2016  There is much more to ... starting the engine. Continental will demonstrate the intelligence of ... Vegas . Through the combination of the keyless ... and biometric elements, the international technology company is opening ... and authentication. "The integration of biometric elements ...
(Date:12/12/2016)... -- Researchers at Trinity College, Dublin, are opening up ... material with Silly Putty. The mixture (known as "G-putty") ... sense pulse, blood pressure, respiration, and even the ... The research team,s findings were published Thursday in ... Due ...
Breaking Biology News(10 mins):